JENCYCLA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Jencycla, and when can generic versions of Jencycla launch?
Jencycla is a drug marketed by Lupin Ltd and is included in one NDA.
The generic ingredient in JENCYCLA is norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the norethindrone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jencycla
A generic version of JENCYCLA was approved as norethindrone by GLENMARK GENERICS on July 22nd, 2010.
Summary for JENCYCLA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 51 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for JENCYCLA |
Drug Sales Revenues: | Drug sales revenues for JENCYCLA |
DailyMed Link: | JENCYCLA at DailyMed |
Pharmacology for JENCYCLA
Drug Class | Progestin |
US Patents and Regulatory Information for JENCYCLA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lupin Ltd | JENCYCLA | norethindrone | TABLET;ORAL-28 | 091323-001 | Mar 28, 2013 | AB2 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |